@article{ref1,
title="PTSD symptoms predict outcome in trauma-informed treatment of intimate partner aggression",
journal="Journal of consulting and clinical psychology",
year="2017",
author="Creech, Suzannah K. and Macdonald, Alexandra and Benzer, Justin K. and Poole, Gina M. and Murphy, Christopher M. and Taft, Casey T.",
volume="85",
number="10",
pages="966-974",
abstract="OBJECTIVE: This study sought to extend findings from a randomized controlled trial of the Strength at Home Men's Program (SAH-M) for intimate partner aggression (IPA) in military veterans by examining the impact of pretreatment posttraumatic stress disorder (PTSD) symptoms on treatment efficacy, and by examining new data on postintervention follow-up for individuals who received SAH-M after completing the enhanced treatment as usual (ETAU) wait-list control condition. <br><br>METHOD: Using data from 125 male veterans who attended the SAH-M program immediately after an intake assessment or after waiting 6-month in the ETAU condition, this study used generalized linear modeling to examine predictors of physical and psychological IPA over a 9-month period of time. <br><br>RESULTS: PTSD symptoms at intake significantly predicted both physical and psychological IPA use, even after accounting for the effects of treatment condition, time, and number of sessions attended. PTSD had a strong association with both physical and psychological IPA. An interaction between PTSD and SAH-M was observed for psychological IPA but not physical IPA, and the magnitude of the effect was not clinically significant. There was a significant effect of SAH-M in reducing IPA in the full sample, including previously unanalyzed outcome data from the ETAU condition. <br><br>CONCLUSION: The study results suggest that while SAH-M does not need to be modified to address the interaction between PTSD and treatment, outcomes could be enhanced through additional direct treatment of PTSD symptoms. <br><br>RESULTS extend prior analyses by demonstrating the effectiveness of SAH-M in reducing use of IPA in both the treatment and ETAU conditions. (PsycINFO Database Record<br><br>(c) 2017 APA, all rights reserved).<p /> <p>Language: en</p>",
language="en",
issn="0022-006X",
doi="10.1037/ccp0000228",
url="http://dx.doi.org/10.1037/ccp0000228"
}